Federated Hermes
SPRO icon

Federated Hermes’s Spero Therapeutics SPRO Stock Holding History

Federated Hermes’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,647
Closed -$3.84K – 2191
2023
Q2 		$3.84K Sell
2,647
-2,206
-45% -$3.78K ﹤0.01% 1930
2023
Q1 		$7.04K Buy
4,853
+4,744
+4,352% +$7.94K ﹤0.01% 1904
2022
Q4 		$189 Sell
109
-1,843
-94% -$3.44K ﹤0.01% 2120
2022
Q3 		$4K Sell
1,952
-627
-24% -$623 ﹤0.01% 1916
2022
Q2 		$2K Buy
+2,579
New +$7.5K ﹤0.01% 1989
2021
Q2 		– Sell
-9,473
Closed -$139K – 2327
2021
Q1 		$139K Buy
+9,473
New +$167K ﹤0.01% 1746

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Federated Hermes's SPRO Position: Q3 2023 in Review

Federated Hermes sold out of Spero Therapeutics (SPRO) in Q3 2023, closing a stake of 2,647 shares — an estimated $3.84K sold.

Federated Hermes first reported a position in SPRO in Q1 2021 and held it in 6 quarters. The position peaked at $139K in Q1 2021. 54 funds tracked by Wall St. Rank hold SPRO as of Q3 2023.

  • Federated Hermes reported no remaining Spero Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Federated Hermes sold 2,647 Spero Therapeutics shares in Q3 2023, an estimated $3.84K.
  • Federated Hermes first reported a position in Spero Therapeutics in Q1 2021 and held it in 6 quarters.
  • Federated Hermes's Spero Therapeutics position peaked at $139K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2023.

Based on Federated Hermes's 13F filing for Q3 2023, filed 13 Nov 2023.